Showing 661 - 680 results of 1,779 for search '(( 10 ((meet decrease) OR (((a decrease) OR (mean decrease)))) ) OR ( 1 b decrease ))*', query time: 0.16s Refine Results
  1. 661
  2. 662
  3. 663

    Pd nanocrystals encapsulated in MOF-derived Ni/N-doped hollow carbon nanosheets for efficient thermal CO oxidation: unveiling the effect of porosity by Ipadeola, Adewale K.

    Published 2023
    “…The obtained Pd/Ni-MOF-HNC possesses hollow carbon sheets with a great surface area (153.05 m2 g−1), pore volume (0.12 cm3 g−1), rich Pd/Ni-Nx active sites, Ni-metal defects, rich N-content (7.53 at%), mixed Pd/Ni-oxide phases, and uniformly distributed ultra-small Pd nanocrystals (7.03 ± 1.10 nm); meanwhile, Pd/Ni-MOF-NC formed without etching had no porosity and less Ni-metal defects. …”
    Get full text
    Get full text
    Get full text
  4. 664
  5. 665

    USING EMBEDDED MACHINE LEARNING IN THE PHYSICAL WORLD TO DETECT TOXICITY IN SPOKEN LANGUAGE by ABU NADA, AHLAM HUSNI

    Published 2023
    “…In our study, quantization demonstrated a significant reduction in model size by almost fourfold and a 3.3-fold decrease in RAM usage. The marginal average F1 score decrease was limited to only 1%. …”
    Get full text
  6. 666
  7. 667
  8. 668
  9. 669
  10. 670

    Effect of Magnetic Baffles and Magnetic Nanofluid on Thermo-Hydraulic Characteristics of Dimple Mini Channel for Thermal Energy Applications by Souayeh, Basma

    Published 2022
    “…In addition, there is a decrease in the pressure drop of 10.82%, 16.778%, and 26.75% when magnetic fields of 1200 G, 1500 G, and 2000 G, respectively, are applied at x = 15 mm, as compared to flow without magnetic field when the pitch = 10 mm. …”
    Get full text
    Get full text
    Get full text
  11. 671
  12. 672
  13. 673
  14. 674
  15. 675
  16. 676
  17. 677
  18. 678
  19. 679
  20. 680

    Understanding the mechanisms mediating cardio-renal benefit of empagliflozin in type 2 diabetes mellitus by Dimitrios, Patoulias

    Published 2023
    “…They have demonstrated1 that empagliflozin treatment resulted in a significant decrease in pulse pressure (PP), mean arterial pressure (MAP) and cardiac workload, compared with placebo; at week 12, placebo-adjusted mean changes from baseline were − 2.5 mmHg for PP, − 2.2 mmHg for MAP and − 315 mmHg x beats per minute (bpm) for cardiac workload (p < 0.0001 for all). …”
    Get full text
    Get full text
    Get full text